NasdaqGS:ACLXBiotechs
Did Anito-cel’s D-Domain Safety Signal at Tandem Just Shift Arcellx's (ACLX) Investment Narrative?
Arcellx announced that a late-breaking abstract on its BCMA-directed CAR T therapy anitocabtagene autoleucel (anito-cel), featuring its novel D-Domain binder, was accepted and presented at the 2026 Tandem Meetings, highlighting preclinical data in relapsed or refractory multiple myeloma.
The preclinical poster suggested that the compact D-Domain binder avoided tonic signaling and off-target activity seen with some other BCMA CAR constructs, potentially pointing to a differentiated safety...